NextFin News — Qingdao Honghu Aviation Technology, a Haier Biomedical subsidiary, completed a Series A financing of 70 million yuan ($9.7 million) on August 3.
The round was subscribed by associated investor Huahai Qiming with 50 million yuan and non-associated Lanxi Juchuang with 20 million yuan, valuing the company at a pre-money 300 million yuan. Proceeds will accelerate European Union Aviation Safety Agency certification, expand production and market deployment of active temperature-controlled containers, increase the number of contracted airlines and build additional overseas operating stations. Honghu’s core products, the RKN-AT1 and RAP-AT1 active air temperature-controlled unit-load devices, have already secured both Civil Aviation Administration of China and U.S. Federal Aviation Administration airworthiness approvals, making the firm the first in the Asia-Pacific region to achieve dual certification for this equipment class.
Founded in 2021 and majority-owned by Shanghai-listed Haier Biomedical, Honghu specializes in leasing and operating active aviation temperature-controlled containers that maintain precise thermal control for high-value pharmaceuticals, biologics and other temperature-sensitive cargo. The company has signed cooperation agreements with more than 20 global airlines and established operations in over 20 core cities, positioning its Chinese-developed containers as an alternative in a market long dominated by a handful of European and U.S. suppliers.
Explore more exclusive insights at nextfin.ai.
